Saturday 17 October 2026
Export PHVS’s income statement to Excel — free account
Pharvaris N.V.
PHVS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 13.8%, free cash flow fell 17.3% and total debt rose 4.31%, each against the same quarter a year earlier.
27.82
1.82
−6.14%
Follow PHVS
Pharvaris N.V. (PHVS) P/E ratio
Pharvaris N.V. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NVAX Novavax, Inc. compare | n/m |
| IRON Disc Medicine, Inc. compare | n/m |
| VRDN Viridian Therapeutics, Inc. compare | n/m |
| PHVS Pharvaris N.V. | n/m |
| FTRE Fortrea Holdings Inc. compare | n/m |
| VERA Vera Therapeutics, Inc. compare | n/m |
| IMNM Immunome, Inc. compare | n/m |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | n/m |
| VCEL Vericel Corporation compare | 83.6× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)